Elizabeth Burns, APRN
Nurse Practitioner · Fayetteville, ARNPI 1023627577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 487 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Amgen at 26.8% of the total. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 487 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$2K
- UCB, Inc.$790
- Pfizer$595
- Novartis$562
- Boehringer Ingelheim$483
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,84999%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 119 | $2,391 |
| AbbVie | 92 | $1,559 |
| UCB, Inc. | 45 | $790 |
| Pfizer | 35 | $595 |
| Novartis | 33 | $562 |
| Boehringer Ingelheim | 29 | $483 |
| E.r. Squibb & Sons, L.L.C. | 18 | $423 |
| Lilly USA, LLC | 24 | $395 |
| Johnson & Johnson | 24 | $378 |
| Mallinckrodt Hospital Products Inc. | 11 | $327 |
| GSK | 16 | $251 |
| AstraZeneca(2 entities) | 9 | $167 |
| Fresenius Kabi USA, LLC | 5 | $91 |
| Genentech USA, Inc. | 3 | $48 |
| Tandem Diabetes Care, Inc. | 2 | $43 |
| Pacira Pharmaceuticals Incorporated | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Corcept Therapeutics | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| CSL Behring | 1 | $19 |
| Soleno Therapeutics, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Midsouth Orthopedics Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Abiomed | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Tonix Medicines, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$108
How this compares
$8,909 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 36 | $355,431 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $281,134 |
| EnbrelEtanercept | 20 | $151,219 |
| Leflunomide | 110 | $6,173 |
| Hydroxychloroquine Sulfate | 130 | $3,627 |
| MethotrexateMethotrexate Sodium | 227 | $3,361 |
| Celecoxib | 48 | $2,486 |
| Sulfasalazine DrSulfasalazine | 69 | $1,643 |
| Duloxetine Hcl | 85 | $982 |
| Prednisone | 131 | $852 |
| Mycophenolate Mofetil | 19 | $571 |
| Pregabalin | 24 | $511 |
| Gabapentin | 34 | $503 |
| Azathioprine | 22 | $391 |
| Folic Acid | 49 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $595 | $281,13413 claims |
| AmgenEnbrel | $2,391 | $151,21920 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $20 | $57119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Fayetteville
- Heather HutchisonFayetteville$6K
- Taylor MarshallFayetteville$6K
- Merideth HanksRogers$157K
- Angela JonesJonesboro$90K
- Tiffany McConathyHot Springs$54K
- Brenna FitzgeraldNorth Little Rock$46K
- Iris KennedyLittle Rock$22K
- Virginia LaliberteHot Springs$21K
- Julia PonderLittle Rock$21K
- Rhonda HillJonesboro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.